These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30952500)

  • 41. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial.
    MacLennan JM; Shackley F; Heath PT; Deeks JJ; Flamank C; Herbert M; Griffiths H; Hatzmann E; Goilav C; Moxon ER
    JAMA; 2000 Jun; 283(21):2795-801. PubMed ID: 10838647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines.
    Jonker EFF; van Ravenhorst MB; Berbers GAM; Visser LG
    Vaccine; 2018 Jun; 36(26):3727-3732. PubMed ID: 29778515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial.
    Buttery JP; Riddell A; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Harnden A; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
    JAMA; 2005 Apr; 293(14):1751-8. PubMed ID: 15827314
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation.
    Shahid NS; Steinhoff MC; Roy E; Begum T; Thompson CM; Siber GR
    Vaccine; 2002 May; 20(17-18):2404-9. PubMed ID: 12009297
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
    Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
    Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children.
    Pichichero M; Casey J; Blatter M; Rothstein E; Ryall R; Bybel M; Gilmet G; Papa T
    Pediatr Infect Dis J; 2005 Jan; 24(1):57-62. PubMed ID: 15665711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines.
    Wysocki J; Tansey S; Brachet E; Baker S; Gruber W; Giardina P; Arora A
    Vaccine; 2010 Nov; 28(49):7779-86. PubMed ID: 20883736
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study.
    Dbaibo G; Tinoco Favila JC; Traskine M; Jastorff A; Van der Wielen M
    Vaccine; 2018 Jun; 36(28):4102-4111. PubMed ID: 29784470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
    Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
    Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
    Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
    Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.
    Bettinger JA; Scheifele DW; Halperin SA; Kellner JD; Vanderkooi OG; Schryvers A; De Serres G; Alcantara J
    Vaccine; 2012 Jun; 30(27):4023-7. PubMed ID: 22537988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children.
    McVernon J; Maclennan J; Buttery J; Oster P; Danzig L; Moxon ER
    Pediatr Infect Dis J; 2002 Aug; 21(8):747-53. PubMed ID: 12192163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera.
    Joseph H; Balmer P; Bybel M; Papa T; Ryall R; Borrow R
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):1-5. PubMed ID: 14715537
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.
    MacDonald NE; Halperin SA; Law BJ; Forrest B; Danzig LE; Granoff DM
    JAMA; 1998 Nov; 280(19):1685-9. PubMed ID: 9832000
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
    Blanchard-Rohner G; Watt H; Kelly DF; Yu LM; Snape MD; Pollard AJ
    Vaccine; 2012 Jun; 30(28):4153-9. PubMed ID: 22554466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
    Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
    BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
    Perrett KP; Jin C; Clutterbuck E; John TM; Winter AP; Kibwana E; Yu LM; Curtis N; Pollard AJ
    J Immunol; 2012 Sep; 189(5):2673-81. PubMed ID: 22855707
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meningococcal serogroup a avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom.
    Joseph H; Miller E; Dawson M; Andrews N; Feavers I; Borrow R
    J Infect Dis; 2001 Sep; 184(5):661-2. PubMed ID: 11494176
    [No Abstract]   [Full Text] [Related]  

  • 60. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.